Parp Inhibitors | search
Click here to view Parp Inhibitors news from 60+ newspapers.
Bookmark or Share- Enhertu demonstrated statistically significant and clinically ...PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to research Lynparza in these settings and to explore its potential in earlier disease.
- PARP inhibitor - WikipediaPARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications, including the treatment of heritable cancers. Several forms of cancer are more dependent on PARP than regular cells, making PARP (PARP1, PARP2 etc.) an attractive target for cancer therapy.
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ...PARP inhibitors (PARPi) were the first approved cancer drugs that specifically targeted the DNA damage response in BRCA1/2 mutated breast and ovarian cancers. Since then, there has been significant advances in our understanding of the mechanisms behind sensitization of tumors to PARP inhibitors and expansion of the use of PARPi to treat several ...
- Discovery of WRN inhibitor HRO761 with synthetic lethality in ... - PubMedThe Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens 1-6.Despite advances in treatment with immune checkpoint inhibitors 7-10, there is an unmet need in the treatment of MSI cancers 11-14.Here we report the structural, biochemical, cellular and pharmacological characterization of the ...
- Understanding and overcoming resistance to PARP inhibitors in cancer ...Poly(ADP-ribose) polymerase (PARP) inhibitors are approved for patients with several forms of cancer, predominantly those harbouring loss-of-function BRCA1/2 mutations or other homologous ...
More
